Levin, Victor A.
Chan, James
Datta, Meenal
Yee, Jennie L.
Jain, Rakesh K.
Funding for this research was provided by:
National Institutes of Health (P01CA080124, NIH-F31HL126449)
Article History
Received: 27 April 2017
Accepted: 12 June 2017
First Online: 19 June 2017
Compliance with ethical standards
:
: V.A.L. received consulting fees from Orbus Therapeutics, Inc., Nativis, Inc., and Bristol-Myers Squibb. R.K.J. received consultant fees from Ophthotech, SPARC, SynDevRx and XTuit. R.K.J owns equity in Enlight, SPARC, SynDevRx and XTuit, and serves on the Board of Directors of XTuit and Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. R.K.J only had access to de-identified data.